anidulafungin has been researched along with Esophageal Diseases in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (85.71) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Clark, K; Fichtenbaum, C; Goldstein, BP; Reboli, A; Schranz, JA; Vazquez, JA | 1 |
| Calis, KA; Estes, KE; Penzak, SR; Walsh, TJ | 1 |
| Diekema, D; Goldstein, BP; Henkel, T; Hollis, R; Messer, S; Pfaller, MA | 1 |
| Murdoch, D; Plosker, GL | 1 |
| Goldstein, BP; Henkel, T; Krause, DS; Simjee, AE; van Rensburg, C; Viljoen, J; Walsh, TJ; Wible, M | 1 |
| Darouiche, RO | 1 |
| Bacher, J; Francesconi, A; Groll, AH; Lyman, CA; Petraitiene, R; Petraitis, V; Piscitelli, SC; Schaufele, RL; Sein, T; Walsh, TJ | 1 |
1 review(s) available for anidulafungin and Esophageal Diseases
| Article | Year |
|---|---|
Pharmacology and antifungal properties of anidulafungin, a new echinocandin.
Topics: Anidulafungin; Animals; Antifungal Agents; Candidiasis; Clinical Trials as Topic; Drug Costs; Drug Interactions; Drug Resistance, Fungal; Echinocandins; Esophageal Diseases; Humans | 2009 |
2 trial(s) available for anidulafungin and Esophageal Diseases
| Article | Year |
|---|---|
A phase 2, open-label study of the safety and efficacy of intravenous anidulafungin as a treatment for azole-refractory mucosal candidiasis.
Topics: Adult; AIDS-Related Opportunistic Infections; Anidulafungin; Antifungal Agents; Azoles; Candidiasis; Candidiasis, Oral; Drug Resistance, Fungal; Echinocandins; Esophageal Diseases; Female; Humans; Male; Middle Aged; Mucous Membrane | 2008 |
A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis.
Topics: Administration, Oral; Adult; Aged; Anidulafungin; Antifungal Agents; Candidiasis; Double-Blind Method; Echinocandins; Esophageal Diseases; Female; Fluconazole; Humans; Infusions, Intravenous; Male; Middle Aged; Peptides, Cyclic | 2004 |
4 other study(ies) available for anidulafungin and Esophageal Diseases
| Article | Year |
|---|---|
In vitro activity of anidulafungin and other agents against esophageal candidiasis-associated isolates from a phase 3 clinical trial.
Topics: Anidulafungin; Antifungal Agents; Candida; Candidiasis; Clinical Trials, Phase III as Topic; Double-Blind Method; Drug Resistance, Fungal; Echinocandins; Esophageal Diseases; Humans; Microbial Sensitivity Tests | 2010 |
Anidulafungin.
Topics: Anidulafungin; Animals; Antifungal Agents; Aspergillosis; Aspergillus; Candida; Candidiasis; Cell Wall; Clinical Trials as Topic; Drug Administration Schedule; Drug Evaluation, Preclinical; Echinocandins; Esophageal Diseases; Glucosyltransferases; Humans; Infusions, Intravenous; Injections, Intravenous; Molecular Structure; New Zealand; Peptides, Cyclic; Time Factors; Treatment Outcome | 2004 |
Echinocandins: ask not what they can do for esophageal candidiasis--ask what studies of esophageal candidiasis can do for them.
Topics: Anidulafungin; Antifungal Agents; Candidiasis; Caspofungin; Echinocandins; Esophageal Diseases; Fungal Proteins; Humans; Lipopeptides; Lipoproteins; Micafungin; Peptides, Cyclic | 2004 |
Dosage-dependent antifungal efficacy of V-echinocandin (LY303366) against experimental fluconazole-resistant oropharyngeal and esophageal candidiasis.
Topics: Amphotericin B; Anidulafungin; Animals; Antifungal Agents; Candidiasis; Candidiasis, Oral; Drug Resistance, Microbial; Echinocandins; Esophageal Diseases; Esophagus; Female; Fluconazole; Immunosuppression Therapy; Peptides, Cyclic; Pharyngeal Diseases; Rabbits; Saliva | 2001 |